Icosavax, Inc.(ICVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ICVX Icosavax, Inc.

Halted 11-22 19:09:19 EST

15.31

+0.00

0.00%

High15.31	Low15.31	Vol0.00
Open15.31	D1 Closing15.31	Amplitude0.00%
Mkt Cap777.79M	Tradable Cap455.03M	Total Shares50.80M
T/O142.68M	T/O Rate0.00%	Tradable Shares29.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ICVX","market":"US","secType":"STK","nameCN":"Icosavax, Inc.","latestPrice":15.31,"timestamp":1708117200000,"preClose":15.31,"halted":3,"volume":0,"delay":0,"floatShares":29720875,"shares":50802709,"eps":-2.19469,"marketStatus":"Halted","change":0,"latestTime":"11-22 19:09:19 EST","open":15.31,"high":15.31,"low":15.31,"amount":142675724.487219,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.19469,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732323600000},"marketStatusCode":4,"adr":0,"listingDate":1627531200000,"exchange":"NASDAQ","adjPreClose":15.31,"volumeRatio":0},"requestUrl":"/m/hq/s/ICVX/wiki","defaultTab":"wiki","newsList":[{"id":"2413752940","title":"Icosavax, Inc. (NASDAQ:ICVX) Shares Sold by Citigroup Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2413752940","media":"AmericanBankin...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2413752940?lang=en_us&edition=fundamental","pubTime":"2024-02-23 19:35","pubTimestamp":1708688128,"startTime":"0","endTime":"0","summary":"Icosavax, Inc. (NASDAQ:ICVX) Shares Sold by Citigroup Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiaGh0dHBzOi8vd3d3LmFtZXJpY2FuYmFua2luZ25ld3MuY29tLzIwMjQvMDIvMjMvaWNvc2F2YXgtaW5jLW5hc2RhcWljdngtc2hhcmVzLXNvbGQtYnktY2l0aWdyb3VwLWluYy5odG1s0gEA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiaGh0dHBzOi8vd3d3LmFtZXJpY2FuYmFua2luZ25ld3MuY29tLzIwMjQvMDIvMjMvaWNvc2F2YXgtaW5jLW5hc2RhcWljdngtc2hhcmVzLXNvbGQtYnktY2l0aWdyb3VwLWluYy5odG1s0gEA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["NQmain","LU0320765646.SGD","LU2210149790.SGD","BK4139","PSQ","ICVX","LU0310800965.SGD","IE00BSNM7G36.USD","BK4566","LU0052756011.USD","LU0128525689.USD","BK4585","TQQQ","BK4539","MNQmain","LU2210150020.SGD","BK4504","SQQQ","LU0098860793.USD","BK4588",".IXIC","LU2095319765.USD","QLD","BK4207","C","QID","LU1162221912.USD","QQQ","NDAQ","BK4534","BK4112","LU1267930227.SGD"],"gpt_icon":0},{"id":"2413342644","title":"M&A Funds And The Stocks Where There Is At Least A 3.5% Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2413342644","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2413342644?lang=en_us&edition=fundamental","pubTime":"2024-02-21 06:40","pubTimestamp":1708468854,"startTime":"0","endTime":"0","summary":"I have been tracking M&A stocks for almost 30 years and sharing insights with the Seeking Alpha community.The article focuses on M&A funds that own at least 3.5% of a stock involved in a merger or buy","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1781056506/image_1781056506.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1781056506/image_1781056506.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4671701-m-and-a-funds-stocks-where-there-is-at-least-3-5-percent-stake","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4154","IE00B19Z3B42.SGD","BK4006","LU0353189763.USD","AMED","IE00B1BXHZ80.USD","ICVX","IE0002270589.USD","BK4539","SOVO","IE0004445239.USD","IE00BJJMRZ35.SGD","LU2236285917.USD","LU0211326755.USD","LU0320765992.SGD","NISTF","IE00B7KXQ091.USD","IE00BFSS8Q28.SGD","BK4533","LU0256863811.USD","IE00B19Z9505.USD","IE00B1XK9C88.USD","UNH","BK4150","BK4532","BK4534","NGMS","AZN","X","IE00BJT1NW94.SGD","JBLU","IE00BJJMRX11.SGD","LU0354030511.USD","LU0211326839.USD","LU0289739699.SGD","LU0122379950.USD","LU0058720904.USD","LU0128525929.USD","LU0354030438.USD","LU0053666078.USD","SAVE","IE00B894F039.SGD","OPCH","LU0353189680.USD","LU0109391861.USD","ALK","LU0316494557.USD","IE00B19Z9P08.USD","LU0211327993.USD","HA"],"gpt_icon":0},{"id":"2412317086","title":"Icosavax Acquisition by AstraZeneca Leads to Delisting and Corporate Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2412317086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2412317086?lang=en_us&edition=fundamental","pubTime":"2024-02-20 21:52","pubTimestamp":1708437142,"startTime":"0","endTime":"0","summary":"Icosavax (ICVX) has released an update. Icosavax, Inc. has been successfully acquired by AstraZeneca Finance and Holdings Inc. through a tender off...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icosavax-acquisition-by-astrazeneca-leads-to-delisting-and-corporate-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icosavax-acquisition-by-astrazeneca-leads-to-delisting-and-corporate-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","ICVX"],"gpt_icon":0},{"id":"2412408251","title":"AstraZeneca completes Icosavax acquisition for $1.1bn","url":"https://stock-news.laohu8.com/highlight/detail?id=2412408251","media":"Pharmaceutical Technology","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2412408251?lang=en_us&edition=fundamental","pubTime":"2024-02-20 16:31","pubTimestamp":1708417888,"startTime":"0","endTime":"0","summary":"AstraZeneca completes Icosavax acquisition for $1.1bn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiUGh0dHBzOi8vd3d3LnBoYXJtYWNldXRpY2FsLXRlY2hub2xvZ3kuY29tL25ld3MvYXN0cmF6ZW5lY2EtaWNvc2F2YXgtYWNxdWlzaXRpb24v0gEA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiUGh0dHBzOi8vd3d3LnBoYXJtYWNldXRpY2FsLXRlY2hub2xvZ3kuY29tL25ld3MvYXN0cmF6ZW5lY2EtaWNvc2F2YXgtYWNxdWlzaXRpb24v0gEA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["BK4568","LU0109394709.USD","LU0889565916.HKD","BK4007","AZN","LU1829250122.USD","LU0320765992.SGD","BK4585","LU2236285917.USD","ICVX","BK4139","BK4539"],"gpt_icon":0},{"id":"2412131042","title":"AstraZeneca PLC AstraZeneca completes acquisition of Icosavax","url":"https://stock-news.laohu8.com/highlight/detail?id=2412131042","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2412131042?lang=en_us&edition=fundamental","pubTime":"2024-02-19 23:00","pubTimestamp":1708354800,"startTime":"0","endTime":"0","summary":"AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle  platform. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US.This announcement may include statements that are not statements of historical fact, or \"forward-looking statements,\" including with respect to AstraZeneca's acquisition of Icosavax. Such forward-looking statements include, but are not limited to, AstraZeneca's beliefs and expectations and statements about the benefits sought to be achieved in AstraZeneca's acquisition of Icosavax, the potential effects of the acquisition on AstraZeneca, as well as the expected benefits and success of IVX-A12 and any combination product. These statements are based upon the current beliefs and expectations of AstraZeneca's managemen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4539","LU1829250122.USD","LU0109394709.USD","LU0320765992.SGD","LU2236285917.USD","VLP","BK4139","AZN","BK4007","BK4568","BK4585","ICVX"],"gpt_icon":0},{"id":"2410831701","title":"Icosavax: Tender Offer With Contingent Value Right","url":"https://stock-news.laohu8.com/highlight/detail?id=2410831701","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2410831701?lang=en_us&edition=fundamental","pubTime":"2024-02-11 19:01","pubTimestamp":1707649279,"startTime":"0","endTime":"0","summary":"AstraZeneca has made a tender offer to acquire Icosavax's shares for $15 per share, with a contingent value right worth up to $5.The CVR includes milestone payouts based on FDA approval and net sales ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4669350-icosavax-tender-offer-with-contingent-value-right","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","ICVX","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","BK4139","BK4568","LU0320765992.SGD","LU0889565916.HKD","BK4539","BK4585","AZN"],"gpt_icon":0},{"id":"2409045408","title":"Centessa Pharmaceuticals: Clinical Advances And Unique Business Model Highlight Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2409045408","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2409045408?lang=en_us&edition=fundamental","pubTime":"2024-02-06 02:48","pubTimestamp":1707158926,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals has a unique business model that combines the flexibility of small-scale biotechs with the support of a large corporation.The company has a strong pipeline of therapeutics add","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208414429/image_1208414429.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208414429/image_1208414429.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4667579-centessa-pharmaceuticals-clinical-advances-unique-business-model-highlight-growth-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["AVDL","ORIC","BK4532","BK4539","FUSN","BK4533","APC","BK4007","LU0109394709.USD","BK4535","ICVX","LU0320765992.SGD","LU0889565916.HKD","CNTA","JAZZ","BK4139"],"gpt_icon":0},{"id":"2406470898","title":"Eye Disruptive Medicine ETF FMED to Start 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2406470898","media":"Vettafi","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2406470898?lang=en_us&edition=fundamental","pubTime":"2024-01-24 08:00","pubTimestamp":1706054400,"startTime":"0","endTime":"0","summary":"Could healthcare innovation be one potent opportunity area to start 2024?Healthcare investing wasn’t necessarily the best in 2023. However, changing conditions could make it an appealing place to invest in the new year. As such, a disruptive medicine ETF like FMED, the Fidelity Disruptive Medicine ETF, could offer one intriguing option for investors.What’s changed for the healthcare tech outlook entering 2024?For one thing, markets are expecting growing M&A activity which can be a big boost for health care companies. When the biggest names in health innovation buy up-and-coming disruptive medicine companies, that can benefit the ETFs that hold the smaller firms’ stocks.For example, FMED holds Icosavax, Inc. , which is currently being acquired by AstraZeneca . Overall, whether that M&A growth comes from a greater appetite for deals from smaller firms facing pressure on balance sheets or an anticipated drop in financing costs, a disruptive medicine ETF like FMED could appeal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://etfdb.com/etf-investing-channel/look-disruptive-medicine-etf-fmed-start-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"etfdb_highlight","symbols":["BK4539","LU1829250122.USD","BK4568","BK4550","BK4139","FDN","LU0320765992.SGD","AZN","LU0109394709.USD","LU2236285917.USD","ICVX","BK4007","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2404663776","title":"AstraZeneca reports positive liver cancer study results for Imfinzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2404663776","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404663776?lang=en_us&edition=fundamental","pubTime":"2024-01-20 05:55","pubTimestamp":1705701340,"startTime":"0","endTime":"0","summary":"AstraZeneca  said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in certain liver cancer patients.  The drugmaker said that Imfinzi, also known as durvalumab, in combination with TACE and bevacizumab was able to lower the risk of death or disease progression by 23% versus TACE in treating patients with hepatocellular carcinoma, or HCC, eligible for embolization.  The study’s primary endpoint was progression-free survival. Bevacizumab is also known as Avastin.  AstraZeneca said that about 20% to 30% of patients with HCC are eligible for embolization. HCC is the most common type of liver cancer. The study results were presented Friday at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.   More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Ico","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4056613-astrazeneca-reports-positive-liver-cancer-study-results-for-imfinzi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","ICVX","LU0889565916.HKD","LU2236285917.USD","BK4539","AZN","LU0320765992.SGD","LU0109394709.USD","BK4139","LU1829250122.USD","BK4568","BK4007"],"gpt_icon":0},{"id":"2404343632","title":"AstraZeneca PNH drug gets first regulatory approval in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2404343632","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404343632?lang=en_us&edition=fundamental","pubTime":"2024-01-20 05:36","pubTimestamp":1705700213,"startTime":"0","endTime":"0","summary":"AstraZeneca  said it has received Japanese regulatory approval for its drug Voydeya, also known as danicopan, in the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH. The drug, which was developed by the company’s Alexion subsidiary, is approved for use in combination with C5 therapy in patients who have had an inadequate response to C5 inhibitors. The Japanese approval is the drug's first. AstraZeneca said Voydeya was developed as an add-on medication to its PNH drugs Ultomiris and Soliris for the approximately 10% to 20% of patients who experience clinically significant extravascular hemolysis while treated with a C5 inhibitor. The company said regulatory submissions for Voydeya are currently under review with various global health authorities.  More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 Ico","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4056605-astrazeneca-pnh-drug-gets-first-regulatory-approval-in-japan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU0889565916.HKD","BK4568","LU0109394709.USD","LU0320765992.SGD","AZN","BK4139","BK4539","BK4007","LU1829250122.USD","ICVX","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2404687537","title":"Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2404687537","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404687537?lang=en_us&edition=fundamental","pubTime":"2024-01-20 02:16","pubTimestamp":1705688160,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek addit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22650692","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["LU1489326972.SGD","PXD","LU1267930813.SGD","LU0795875086.SGD","LU0068578508.USD","XOM","SG9999014542.SGD","BK4211","IE00B1XK9C88.USD","LU0912757837.SGD","SG9999002232.USD","LU1732800096.USD","IE00BWXC8680.SGD","LU0266512127.USD","HARP","IE00B19Z3581.USD","BK4500","IE00B19Z3B42.SGD","LU0433182093.SGD","BK4585","LU0868494617.USD","SG9999001440.SGD","SG9999002224.SGD","LU0098860793.USD","LU0300736062.USD","LU0300736492.USD","IE00BKDWB100.SGD","BK4139","LU1169589451.USD","BK4539","LU1066051498.USD","BK4592","IE00B7SZLL34.SGD","LU1162221912.USD","LU0878866978.SGD","SG9999002521.SGD","ISBC","LU0792757196.USD","LU0456854461.SGD","LU0122376428.USD","LU0320765646.SGD","HA","IE0002270589.USD","LU0985489474.SGD","LU2347655156.SGD","LU0368265418.SGD","BK4588","LU2133065610.SGD","ICVX","BK4213"],"gpt_icon":0},{"id":"2404507405","title":"Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2404507405","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2404507405?lang=en_us&edition=fundamental","pubTime":"2024-01-19 23:13","pubTimestamp":1705677235,"startTime":"0","endTime":"0","summary":"Icosavax  fell 1.7% as AstraZeneca  withdrew its filing for HSR approval for the planned sale and refiled it.  On Wednesday, the companies withdrew and refiled to give the Federal Trade Commission additional time to review the planned deal, according to a filing on Friday. The HSR waiting period now expires on Feb. 16.  AstraZeneca  agreed to acquire U.S. vaccine developer Icosavax  in a deal valued at up to $1.1 billion last month. The deal values Icosavax  at $15/share in cash at closing, plus a non-tradable contingent value right for up to $5/share in cash if certain milestones are met.  More on Icosavax  Icosavax CVR Seems Fairly Valued AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition Icosavax deal CVR based on FDA approval for IVX-A12, sales in EU, UK, Canada Biggest stock movers today: Oracle, Workhorse Group, Icosavax and more Seeking Alpha’s Quant Rating on Icosavax","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4056469-icosavax-ticks-lower-as-hsr-filing-for-astrazeneca-deal-withdrawn-refiled","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00B19Z3B42.SGD","ORCL","LU0130102774.USD","LU0109394709.USD","LU1435385759.SGD","PSQ","MNQmain","LU0289960550.SGD","LU1506573853.SGD","LU1429558221.USD","QID","BK4568","NQmain","TQQQ","WKHS","LU0320765992.SGD",".IXIC","BK4588","BK4139","LU0175139822.USD","LU0256863811.USD","LU0348723411.USD","AZN","LU0980610538.SGD","LU0661504455.SGD","LU0082616367.USD","LU0648001328.SGD","SQQQ","IE00BBT3K403.USD","LU1803068979.SGD","LU0068578508.USD","LU1935042991.SGD","ICVX","LU0965509283.SGD","QLD","LU0433182093.SGD","LU0878866978.SGD","LU2236285917.USD","BK4585","BK4539","LU0208291251.USD","IE0002270589.USD","BK4534","LU0985489474.SGD","BK4528","QQQ","BK4581","IE00BLSP4239.USD","LU1201861249.SGD","LU0109392836.USD"],"gpt_icon":0},{"id":"2401351884","title":"Icosavax CVR Seems Fairly Valued","url":"https://stock-news.laohu8.com/highlight/detail?id=2401351884","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2401351884?lang=en_us&edition=fundamental","pubTime":"2024-01-06 04:45","pubTimestamp":1704487511,"startTime":"0","endTime":"0","summary":"AstraZeneca plans to acquire Icosavax for $15/share in cash and one non-tradable CVR per share.The CVR pays out $4/share upon FDA approval of the vaccine candidate and $1/share upon achieving over $20","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417011459/image_1417011459.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417011459/image_1417011459.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4661381-icosavax-cvr-seems-fairly-valued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","ICVX","LU0889565916.HKD","CVR","LU2236285917.USD","BK4539","LU0320765992.SGD","BK4161","LU0109394709.USD","BK4568","BK4139","LU1829250122.USD","AZN","BK4007"],"gpt_icon":0},{"id":"2400872649","title":"Icosavax Sued Over AstraZeneca Takeover Conflicts, Projections","url":"https://stock-news.laohu8.com/highlight/detail?id=2400872649","media":"Bloomberg Law","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2400872649?lang=en_us&edition=fundamental","pubTime":"2024-01-04 01:19","pubTimestamp":1704302356,"startTime":"0","endTime":"0","summary":"Icosavax Sued Over AstraZeneca Takeover Conflicts, Projections","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMiZmh0dHBzOi8vbmV3cy5ibG9vbWJlcmdsYXcuY29tL2xpdGlnYXRpb24vaWNvc2F2YXgtc3VlZC1vdmVyLWFzdHJhemVuZWNhLXRha2VvdmVyLWNvbmZsaWN0cy1wcm9qZWN0aW9uc9IBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMiZmh0dHBzOi8vbmV3cy5ibG9vbWJlcmdsYXcuY29tL2xpdGlnYXRpb24vaWNvc2F2YXgtc3VlZC1vdmVyLWFzdHJhemVuZWNhLXRha2VvdmVyLWNvbmZsaWN0cy1wcm9qZWN0aW9uc9IBAA?oc=5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"redbox_crawler","symbols":["BK4139","BK4585","LU2236285917.USD","LU0889565916.HKD","AZN","BK4007","LU0109394709.USD","BK4539","LU1829250122.USD","LU0320765992.SGD","BK4568","ICVX"],"gpt_icon":0},{"id":"2400639856","title":"Icosavax Cut to Neutral From Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2400639856","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2400639856?lang=en_us&edition=fundamental","pubTime":"2024-01-02 18:43","pubTimestamp":1704192180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ICVX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2024 05:43 ET (10:43 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICVX","BK4139","BK4539"],"gpt_icon":0},{"id":"2394799309","title":"BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2394799309","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2394799309?lang=en_us&edition=fundamental","pubTime":"2023-12-28 14:57","pubTimestamp":1703746665,"startTime":"0","endTime":"0","summary":"BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines.The company has acquired MediLink Therapeutics' ADC technology and is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4660043-biontechs-strategic-shift-diversifying-into-cancer-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4588","IE00B19Z3581.USD","LU0170899867.USD","LU0456855351.SGD","BK4139","LU0390134368.USD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0109394709.USD","LU1093756168.USD","BK4592","LU1057294990.SGD","BK4099","GMAB","IMGN","LU0889565916.HKD","BK4550","IE0002270589.USD","BK4574","LU0320765992.SGD","SGXZ57979304.SGD","BMRN","BK4555","IE00B7SZLL34.SGD","BK4007","BK4535","LU0868494617.USD","SGEN","BK4551","LU1066053197.SGD","LU1066051498.USD","BK4581","BK4533","SG9999002232.USD","LU0289739699.SGD","IE00BLSP4239.USD","BK4566","SG9999001176.SGD","ALNY","SG9999003800.SGD","LU0122379950.USD","SG9999013999.USD","PFE","SG9999002224.SGD","F","BNTX","ICVX","IE00B19Z3B42.SGD","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2394229640","title":"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, In","url":"https://stock-news.laohu8.com/highlight/detail?id=2394229640","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2394229640?lang=en_us&edition=fundamental","pubTime":"2023-12-27 03:28","pubTimestamp":1703618880,"startTime":"0","endTime":"0","summary":"BALA CYNWYD, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22564941","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4007","BK4539","CNSL","RAIN","BK4115","BK4139","ICVX","BK4211","ISBC"],"gpt_icon":0},{"id":"2393401438","title":"Chief Medical Officer Niranjan Kanesa-thasan Sells 11,884 Shares of Icosavax Inc (ICVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2393401438","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2393401438?lang=en_us&edition=fundamental","pubTime":"2023-12-24 16:01","pubTimestamp":1703404862,"startTime":"0","endTime":"0","summary":"According to a recent SEC filing, Niranjan Kanesa-thasan, the Chief Medical Officer of Icosavax Inc , sold 11,884 shares of the company on December 20, 2023. The transaction was executed at an average price of $15.46 per share, indicating a total sale amount of $183,686.64.GuruFocus has detected 4 Warning Signs with ICVX.Icosavax Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of vaccine candidates. The company's proprietary technology platform is designed to enable the development of vaccines that elicit robust immune responses, with a primary focus on preventing diseases caused by infectious pathogens.Over the past year, the insider has sold a total of 17,001 shares of Icosavax Inc and has not made any purchases of the stock. The recent sale by the insider is part of a broader trend observed over the past year, where there have been 19 insider sells and no insider buys.On the date of the insider's most recent transaction, shares of Icos","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zbRpo5xL_JjkH1yoYXNE.g--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/34ee3477c8a419ef0c7c3c40c29490d1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zbRpo5xL_JjkH1yoYXNE.g--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/34ee3477c8a419ef0c7c3c40c29490d1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chief-medical-officer-niranjan-kanesa-080102579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","ICVX","BK4139"],"gpt_icon":0},{"id":"2392021960","title":"11 Best European Dividend Stocks to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2392021960","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2392021960?lang=en_us&edition=fundamental","pubTime":"2023-12-18 20:58","pubTimestamp":1702904296,"startTime":"0","endTime":"0","summary":"In this article, we will take a detailed look at the11 Best European Dividend Stocks to Buy.For a quick overview of such stocks, read our article5Best European Dividend Stocks to Buy.European equities were laggards when compared to US stocks in 2023 as economic activity in the Eurozone continues to contract. In December, the Eurozone saw its economic activity shrink for the seventh straight month. However, analysts at Citigroup believe 2024 will bring a positive change as they expect European stocks to hit record high in the year. Citigroup analyst Beata Manthey recently said that bad news is already priced in for European stocks. The analyst expects the regional benchmark Stoxx 600 Index to end 2024 at 510 points. As of December 18 the index was at 476 points. Citigroup’s analyst said the market has become too pessimistic when it comes to earnings growth expectations for European stocks. This development, she believes, has created a buffer zone to protect stocks from further declines ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WMYOcUppg4GgaHzX_rotPw--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/c744b8e380d10e948e557e78b8e86ff3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WMYOcUppg4GgaHzX_rotPw--~B/aD0xMjgwO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/c744b8e380d10e948e557e78b8e86ff3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/11-best-european-dividend-stocks-125816419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SHEL","NQmain","LU2384288077.EUR","LU0320765646.SGD","LU1621768206.USD","BK4550","LU0122379950.USD","AZN","LU1093756168.USD","LU1914381329.SGD","TEL","PSQ","ICVX","LU1039938227.USD","LU0058720904.USD","IE00B19Z9P08.USD","NVT","BK4096","IE0002270589.USD","LU0300736062.USD","FERG","LU0321505868.SGD","LU1571399168.USD","LU0320765992.SGD","TQQQ","VZ","BK4539","MNQmain","MO","SQQQ","SGXZ57979304.SGD","LU0648000940.SGD","LU1057294990.SGD","SG9999001176.SGD","LU0868494617.USD","IE00BBT3K403.USD",".IXIC","BK4075","QLD","PFE","IE00B19Z3B42.SGD","QID","BK4104","SG9999001176.USD","LU0061475181.USD","QQQ","BK4534","BK4559","LU1066051498.USD","CRH"],"gpt_icon":0},{"id":"2391662904","title":"Insider Sell Alert: Chief Business Officer Cassia Cearley Sells 8,759 Shares of Icosavax Inc (ICVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2391662904","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2391662904?lang=en_us&edition=fundamental","pubTime":"2023-12-16 22:02","pubTimestamp":1702735328,"startTime":"0","endTime":"0","summary":"In a recent transaction on December 13, 2023, Cassia Cearley, the Chief Business Officer of Icosavax Inc , sold 8,759 shares of the company's stock. This move has caught the attention of investors and market analysts, as insider transactions can provide valuable insights into a company's prospects and the confidence level of its executives.Cassia Cearley has been serving as the Chief Business Officer of Icosavax Inc, a biopharmaceutical company focused on the discovery and development of vaccines against infectious diseases. In this role, Cearley is responsible for the company's business development, strategic partnerships, and commercial planning. The insider's actions, including stock transactions, are closely monitored as they can reflect the insider's belief in the company's future performance.Insider Trends and Market ReactionThe market often reacts to insider tran","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QeHMj0QEhl18auIQrTx9fA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/d09eb9611adc2dcec9cf892d240e8999","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QeHMj0QEhl18auIQrTx9fA--~B/aD01NDM7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/d09eb9611adc2dcec9cf892d240e8999"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-sell-alert-chief-business-140208045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ICVX","BK4539","VLP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.icosavax.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0.5039},{"period":"ytd","weight":-0.0286}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.","exchange":"NASDAQ","name":"Icosavax, Inc.","nameEN":"Icosavax, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Icosavax, Inc.(ICVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Icosavax, Inc.(ICVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Icosavax, Inc.,ICVX,Icosavax, Inc.股票,Icosavax, Inc.股票老虎,Icosavax, Inc.股票老虎国际,Icosavax, Inc.行情,Icosavax, Inc.股票行情,Icosavax, Inc.股价,Icosavax, Inc.股市,Icosavax, Inc.股票价格,Icosavax, Inc.股票交易,Icosavax, Inc.股票购买,Icosavax, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Icosavax, Inc.(ICVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Icosavax, Inc.(ICVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}